MYC protein expression is associated with poor prognosis in diffuse large B cell lymphoma patients treated with RCHOP chemotherapy |
| |
| Authors: | Min Zhou Jing Wang Jian Ouyang Jing-yan Xu Bing Chen Qi-guo Zhang Rong-fu Zhou Yong-gong Yang Xiao-yan Shao Yong Xu Ya-mei Chen Xiang-shan Fan Hong-yan Wu |
| |
| Affiliation: | 1. Department of Hematology, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210008, People’s Republic of China
2. Department of Pathology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, 210008, People’s Republic of China
|
| |
| Abstract: | This study aims to investigate the prognostic significance of the MYC protein expression in diffuse large B cell lymphoma (DLBCL) patients treated with RCHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone). A total of 60 patients with DLBCL from 2008 to 2013 were included. Formalin-fixed, paraffin-embedded DLBCL samples were analyzed for MYC protein expression and divided into high or low MYC group. The MYC protein expression and the international prognostic variables were evaluated. The high MYC protein expression predicted a shorter 3-year estimated overall survival (OS) and progression-free survival (PFS) versus the low MYC protein expression (57 % vs. 96 %, P?P?=?0.001, respectively). Multivariate analysis confirmed the prognostic significance of the MYC protein expression for both OS (HR, 11.862; 95 % CI, 1.462–96.218; P?=?0.021) and PFS (HR, 6.073; 95 % CI, 1.082–34.085; P?=?0.040). MYC protein expression with International Prognostic Index (IPI) score distinguished patients into three risk groups with different 3-year OS rates (χ 2 23.079; P?χ 2 15.862; P?
|
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
